Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacia Vestra, Deramciclane Could Be Detailed By Specialized Rep Force

Executive Summary

Pharmacia is considering creating a psychiatric sales force to promote its antidepressant Vestra (reboxetine), which is pending at FDA, as well as Orion Pharma's late-stage anxiety drug deramciclane.

You may also be interested in...

Pharmacia TNF-Inhibitor’s Monthly Dosing Could Offer Marketing Advantage

Pharmacia's experimental tumor necrosis factor inhibitor CDP-870 could gain a competitive advantage through a once-monthly dosing schedule

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts